Want to see SE:XINT full AI Analyst Report?
XINT Stock Chart & Stats
kr0.28
-kr0.02(-4.02%)
At close: 4:00 PM EST
kr0.28
-kr0.02(-4.02%)
Day’s Range― - ―
52-Week Rangekr0.16 - kr0.53
Previous CloseN/A
Volume22.80K
Average Volume (3M)554.92K
Market Cap
kr160.20M
Enterprise Valuekr208.12
Total Cash (Recent Filing)kr23.21M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 28, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding861,266,850
10 Day Avg. Volume503,836
30 Day Avg. Volume554,918
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)-37.15
Price to Sales (P/S)85.84
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)kr11.13M
Bulls Say, Bears Say
Bulls Say
Proprietary Integrin PlatformXintela’s proprietary integrin technology underpins programs in regenerative medicine, oncology and diagnostics. As a platform asset it can generate multiple clinical and diagnostic candidates or licensing deals, providing durable strategic optionality beyond any single asset.
No Debt / Low Financial LeverageZero reported debt materially lowers near-term refinancing and interest-service pressure, giving management flexibility to time capital raises or pursue partnerships. This structural de-risking supports survival through development cycles despite operating losses.
Positive Gross Profit In 2024–2025Reported positive gross profit indicates product or program-level economics can be attractive once scaleable revenue is captured. This suggests underlying unit economics could support margin expansion if commercial traction or licensing revenue is achieved.
Bears Say
Persistent Heavy Operating Cash BurnSustained operating cash outflows of roughly -40M to -53M annually create ongoing funding needs, forcing repeated external financing or dilutive raises. Over the medium term this heightens execution risk and can delay programs if capital access tightens.
Negative Shareholders' EquityA negative equity position weakens balance-sheet resilience, limits borrowing or partnership leverage, and signals accumulated losses. Structurally this increases the probability of dilutive capital events and constrains strategic flexibility over coming quarters.
Small, Volatile Revenue And Persistent Net LossesVolatile and small revenues, combined with sustained operating and net losses, indicate commercialization traction is limited. Without consistent revenue growth or milestone monetization, profitability remains distant and business viability hinges on successful R&D outcomes or partnerships.
Xintela AB News
XINT FAQ
What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was kr0.16 and its highest was kr0.53 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is kr160.20M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s upcoming earnings report date is Aug 28, 2026 which is in 10 days.
How were Xintela AB’s earnings last quarter?
Xintela AB released its earnings results on May 29, 2026. The company reported -kr0.01 earnings per share for the quarter, the consensus estimate of -kr0.01 by kr0.
Is Xintela AB overvalued?
According to Wall Street analysts Xintela AB’s price is currently Overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate is -0.01.
How many shares outstanding does Xintela AB have?
Xintela AB has 861,266,850 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Xintela AB reported an EPS of -kr0.01 in its last earnings report, expectations of -kr0.01. Following the earnings report the stock price went down -5.394%.
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in SE:XINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xintela AB
Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XINMARK, a patented marker technology used to accurately identify and isolate specific stem cells that can develop into cartilage cells. Their product portfolio includes XSTEM, a stem cell-based therapy undergoing clinical trials for treating knee osteoarthritis and persistent leg ulcers. They also offer EQSTEM, another stem cell product, for managing joint conditions in horses. In oncology, Xintela is engaged in the preclinical development of therapeutic antibodies designed to combat aggressive cancers like glioblastoma, a severe brain tumor, and triple-negative breast cancer.
Technical Analysis
Isofol Medical AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―